Review





Similar Products

90
Vertex Pharmaceuticals vertex-pharmaceuticals cystic fibrosis research innovation award
Vertex Pharmaceuticals Cystic Fibrosis Research Innovation Award, supplied by Vertex Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/innovator/nct04395820-15-7-7?v=Vertex+Pharmaceuticals
Average 90 stars, based on 1 article reviews
vertex-pharmaceuticals cystic fibrosis research innovation award - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Materialise NV mimics innovation suite software
Mimics Innovation Suite Software, supplied by Materialise NV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/innovator/nct06297109-10-16-20?v=Materialise+NV
Average 90 stars, based on 1 article reviews
mimics innovation suite software - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

86
Sysmex Corporation innovance d dimer assay
Innovance D Dimer Assay, supplied by Sysmex Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/innovator/pmc13122200-80-8-13?v=Sysmex+Corporation
Average 86 stars, based on 1 article reviews
innovance d dimer assay - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Siemens Healthineers innovance pfa 200 system
PSG6 inhibits platelet function without inducing cytotoxicity or impairing hemostasis . (A) Platelet cytotoxicity by LDH release. (B) Platelet apoptosis by Annexin-V (phosphatidylserine externalization). (C) Platelet viability by Calcein-AM. (D) Platelet aggregation induced with TRAP-6 at 5 μM of gentisic acid linked to TPP by different chain lengths. (E) P-Selectin expression (PE-CD62p). (F) Activated IIb/IIIa (FITC-Fibrinogen) (G) Representative image of clot retraction assay and clot weight after 2 h. <t>(H–I)</t> <t>PFA-200</t> closure times in collagen/ADP and collagen/epinephrine cartridges, respectively. Eptifibatide (EPT) 10 μM was used as a control for G–I. (J) Representative fluorescence microscopy images of thrombus formation on 3 different areas of collagen-coated channels under arterial shear conditions, showing vehicle (DMSO 0.2%) versus PSG6 at 10 μM. Thrombus coverage is expressed as the percentage of surface area occupied by fluorescently marked platelets. (K) Quantification of thrombus area based on fluorescence intensity of platelet-specific markers, using a defined threshold to exclude non-platelet signals. For A-F, data is shown as mean ± SEM (n = 6). One-way ANOVA – Bonferroni was performed as a statistical analysis. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 vs vehicle (DMSO 0.2%). For G-K, data are -presented as mean ± SEM (n = 3). One-way ANOVA with Bonferroni's post hoc test was used for statistical analysis. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. vehicle (DMSO 0.2%).
Innovance Pfa 200 System, supplied by Siemens Healthineers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/innovator/pmc13202023-72-19-22?v=Siemens+Healthineers
Average 86 stars, based on 1 article reviews
innovance pfa 200 system - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Innov X Systems ther innov regul sci 2018
PSG6 inhibits platelet function without inducing cytotoxicity or impairing hemostasis . (A) Platelet cytotoxicity by LDH release. (B) Platelet apoptosis by Annexin-V (phosphatidylserine externalization). (C) Platelet viability by Calcein-AM. (D) Platelet aggregation induced with TRAP-6 at 5 μM of gentisic acid linked to TPP by different chain lengths. (E) P-Selectin expression (PE-CD62p). (F) Activated IIb/IIIa (FITC-Fibrinogen) (G) Representative image of clot retraction assay and clot weight after 2 h. <t>(H–I)</t> <t>PFA-200</t> closure times in collagen/ADP and collagen/epinephrine cartridges, respectively. Eptifibatide (EPT) 10 μM was used as a control for G–I. (J) Representative fluorescence microscopy images of thrombus formation on 3 different areas of collagen-coated channels under arterial shear conditions, showing vehicle (DMSO 0.2%) versus PSG6 at 10 μM. Thrombus coverage is expressed as the percentage of surface area occupied by fluorescently marked platelets. (K) Quantification of thrombus area based on fluorescence intensity of platelet-specific markers, using a defined threshold to exclude non-platelet signals. For A-F, data is shown as mean ± SEM (n = 6). One-way ANOVA – Bonferroni was performed as a statistical analysis. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 vs vehicle (DMSO 0.2%). For G-K, data are -presented as mean ± SEM (n = 3). One-way ANOVA with Bonferroni's post hoc test was used for statistical analysis. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. vehicle (DMSO 0.2%).
Ther Innov Regul Sci 2018, supplied by Innov X Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/innovator/pm42285645-225-0-1?v=Innov+X+Systems
Average 86 stars, based on 1 article reviews
ther innov regul sci 2018 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Innov X Systems innov comput sci j
PSG6 inhibits platelet function without inducing cytotoxicity or impairing hemostasis . (A) Platelet cytotoxicity by LDH release. (B) Platelet apoptosis by Annexin-V (phosphatidylserine externalization). (C) Platelet viability by Calcein-AM. (D) Platelet aggregation induced with TRAP-6 at 5 μM of gentisic acid linked to TPP by different chain lengths. (E) P-Selectin expression (PE-CD62p). (F) Activated IIb/IIIa (FITC-Fibrinogen) (G) Representative image of clot retraction assay and clot weight after 2 h. <t>(H–I)</t> <t>PFA-200</t> closure times in collagen/ADP and collagen/epinephrine cartridges, respectively. Eptifibatide (EPT) 10 μM was used as a control for G–I. (J) Representative fluorescence microscopy images of thrombus formation on 3 different areas of collagen-coated channels under arterial shear conditions, showing vehicle (DMSO 0.2%) versus PSG6 at 10 μM. Thrombus coverage is expressed as the percentage of surface area occupied by fluorescently marked platelets. (K) Quantification of thrombus area based on fluorescence intensity of platelet-specific markers, using a defined threshold to exclude non-platelet signals. For A-F, data is shown as mean ± SEM (n = 6). One-way ANOVA – Bonferroni was performed as a statistical analysis. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 vs vehicle (DMSO 0.2%). For G-K, data are -presented as mean ± SEM (n = 3). One-way ANOVA with Bonferroni's post hoc test was used for statistical analysis. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. vehicle (DMSO 0.2%).
Innov Comput Sci J, supplied by Innov X Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/innovator/pm42288791-579-0-0?v=Innov+X+Systems
Average 86 stars, based on 1 article reviews
innov comput sci j - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Innov X Systems int j innov adv stud
PSG6 inhibits platelet function without inducing cytotoxicity or impairing hemostasis . (A) Platelet cytotoxicity by LDH release. (B) Platelet apoptosis by Annexin-V (phosphatidylserine externalization). (C) Platelet viability by Calcein-AM. (D) Platelet aggregation induced with TRAP-6 at 5 μM of gentisic acid linked to TPP by different chain lengths. (E) P-Selectin expression (PE-CD62p). (F) Activated IIb/IIIa (FITC-Fibrinogen) (G) Representative image of clot retraction assay and clot weight after 2 h. <t>(H–I)</t> <t>PFA-200</t> closure times in collagen/ADP and collagen/epinephrine cartridges, respectively. Eptifibatide (EPT) 10 μM was used as a control for G–I. (J) Representative fluorescence microscopy images of thrombus formation on 3 different areas of collagen-coated channels under arterial shear conditions, showing vehicle (DMSO 0.2%) versus PSG6 at 10 μM. Thrombus coverage is expressed as the percentage of surface area occupied by fluorescently marked platelets. (K) Quantification of thrombus area based on fluorescence intensity of platelet-specific markers, using a defined threshold to exclude non-platelet signals. For A-F, data is shown as mean ± SEM (n = 6). One-way ANOVA – Bonferroni was performed as a statistical analysis. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 vs vehicle (DMSO 0.2%). For G-K, data are -presented as mean ± SEM (n = 3). One-way ANOVA with Bonferroni's post hoc test was used for statistical analysis. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. vehicle (DMSO 0.2%).
Int J Innov Adv Stud, supplied by Innov X Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/innovator/pm42265803-183-0-2?v=Innov+X+Systems
Average 86 stars, based on 1 article reviews
int j innov adv stud - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

86
Innov X Systems innov technol tech cardiothorac vasc surg 2020
PSG6 inhibits platelet function without inducing cytotoxicity or impairing hemostasis . (A) Platelet cytotoxicity by LDH release. (B) Platelet apoptosis by Annexin-V (phosphatidylserine externalization). (C) Platelet viability by Calcein-AM. (D) Platelet aggregation induced with TRAP-6 at 5 μM of gentisic acid linked to TPP by different chain lengths. (E) P-Selectin expression (PE-CD62p). (F) Activated IIb/IIIa (FITC-Fibrinogen) (G) Representative image of clot retraction assay and clot weight after 2 h. <t>(H–I)</t> <t>PFA-200</t> closure times in collagen/ADP and collagen/epinephrine cartridges, respectively. Eptifibatide (EPT) 10 μM was used as a control for G–I. (J) Representative fluorescence microscopy images of thrombus formation on 3 different areas of collagen-coated channels under arterial shear conditions, showing vehicle (DMSO 0.2%) versus PSG6 at 10 μM. Thrombus coverage is expressed as the percentage of surface area occupied by fluorescently marked platelets. (K) Quantification of thrombus area based on fluorescence intensity of platelet-specific markers, using a defined threshold to exclude non-platelet signals. For A-F, data is shown as mean ± SEM (n = 6). One-way ANOVA – Bonferroni was performed as a statistical analysis. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 vs vehicle (DMSO 0.2%). For G-K, data are -presented as mean ± SEM (n = 3). One-way ANOVA with Bonferroni's post hoc test was used for statistical analysis. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. vehicle (DMSO 0.2%).
Innov Technol Tech Cardiothorac Vasc Surg 2020, supplied by Innov X Systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/innovator/pm42285639-279-1-0?v=Innov+X+Systems
Average 86 stars, based on 1 article reviews
innov technol tech cardiothorac vasc surg 2020 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


PSG6 inhibits platelet function without inducing cytotoxicity or impairing hemostasis . (A) Platelet cytotoxicity by LDH release. (B) Platelet apoptosis by Annexin-V (phosphatidylserine externalization). (C) Platelet viability by Calcein-AM. (D) Platelet aggregation induced with TRAP-6 at 5 μM of gentisic acid linked to TPP by different chain lengths. (E) P-Selectin expression (PE-CD62p). (F) Activated IIb/IIIa (FITC-Fibrinogen) (G) Representative image of clot retraction assay and clot weight after 2 h. (H–I) PFA-200 closure times in collagen/ADP and collagen/epinephrine cartridges, respectively. Eptifibatide (EPT) 10 μM was used as a control for G–I. (J) Representative fluorescence microscopy images of thrombus formation on 3 different areas of collagen-coated channels under arterial shear conditions, showing vehicle (DMSO 0.2%) versus PSG6 at 10 μM. Thrombus coverage is expressed as the percentage of surface area occupied by fluorescently marked platelets. (K) Quantification of thrombus area based on fluorescence intensity of platelet-specific markers, using a defined threshold to exclude non-platelet signals. For A-F, data is shown as mean ± SEM (n = 6). One-way ANOVA – Bonferroni was performed as a statistical analysis. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 vs vehicle (DMSO 0.2%). For G-K, data are -presented as mean ± SEM (n = 3). One-way ANOVA with Bonferroni's post hoc test was used for statistical analysis. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. vehicle (DMSO 0.2%).

Journal: Redox Biology

Article Title: PSG6: A mitochondrially-targeted gentisic acid derivative exerts antiplatelet action via mitochondrial complex I inhibition

doi: 10.1016/j.redox.2026.104200

Figure Lengend Snippet: PSG6 inhibits platelet function without inducing cytotoxicity or impairing hemostasis . (A) Platelet cytotoxicity by LDH release. (B) Platelet apoptosis by Annexin-V (phosphatidylserine externalization). (C) Platelet viability by Calcein-AM. (D) Platelet aggregation induced with TRAP-6 at 5 μM of gentisic acid linked to TPP by different chain lengths. (E) P-Selectin expression (PE-CD62p). (F) Activated IIb/IIIa (FITC-Fibrinogen) (G) Representative image of clot retraction assay and clot weight after 2 h. (H–I) PFA-200 closure times in collagen/ADP and collagen/epinephrine cartridges, respectively. Eptifibatide (EPT) 10 μM was used as a control for G–I. (J) Representative fluorescence microscopy images of thrombus formation on 3 different areas of collagen-coated channels under arterial shear conditions, showing vehicle (DMSO 0.2%) versus PSG6 at 10 μM. Thrombus coverage is expressed as the percentage of surface area occupied by fluorescently marked platelets. (K) Quantification of thrombus area based on fluorescence intensity of platelet-specific markers, using a defined threshold to exclude non-platelet signals. For A-F, data is shown as mean ± SEM (n = 6). One-way ANOVA – Bonferroni was performed as a statistical analysis. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 vs vehicle (DMSO 0.2%). For G-K, data are -presented as mean ± SEM (n = 3). One-way ANOVA with Bonferroni's post hoc test was used for statistical analysis. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. vehicle (DMSO 0.2%).

Article Snippet: Subsequently, the sample was loaded into the Collagen/Epinephrine or Collagen/ADP cartridge, and the closure time was measured in the Innovance PFA-200 system (Siemens Healthcare Diagnostics Products, Munich, Germany).

Techniques: Expressing, Control, Fluorescence, Microscopy, Shear